With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to conduct a clinical study evaluating the combination of its Allurion Program ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...